NCT07440446Not yet recruiting
Effect of Acetominophen an Gait Fatigue in Multiple Sclerosis
Effect of Antipyretics in Gait Fatigue in Multiple Sclerosis
Source: ClinicalTrials.gov · Last updated 17 Mar 2026
Brief summary (registry, in English)
The goal of this observational study is to compare the impact of an antipyretic, acetaminophen to a placebo on gait fatigue in persons with multiple sclerosis (MS). The primary question this study is asking is the following: will the antipyretic effects of acetaminophen result in less gait fatigue in persons with MS? Participants will be asked to come for two sessions over a 1 week period. In the first week, subjects will be blind-randomized into either the acetaminophen or placebo group. They will then undergo a test to determine their gait speed by performing two 25 foot walks at their best comfortable pace. The walks will be 1 minute apart. The average speed from those 2 walks will be obtained. Subjects will then take either the acetaminophen or the placebo. Following a 45 minute rest period they will then get on a treadmill and will walk at the previously determined speed for as long as they can. Walking will stop if the subject can no longer maintain the speed or if they wish to no longer continue. The subjects will wear a safety harness at all times during the walk to prevent falls. Heart rate and core body temperature will be measured via skin sensors. One week later the subjects will return and repeat the procedure but this time in the opposite condition. Subjects who took the acetaminophen will take the placebo and subjects who took the placebo will take the acetaminophen. The difference between distance walked in the 2 conditions will be compared.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 20 (estimated)
- First submitted
- 23 Feb 2026
- Start date
- Mar 2026
- Primary completion date
- Dec 2026
- Lead sponsor
- Hunter College of City University of New York
- Diseases
- Multiple sclerosis
- NCT number
- NCT07440446
What you commit to
- Study type: Observational
- Planned participants: 20
- From Mar 2026 to the primary completion date, Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Recent use of steroids
Other illness
- Any non-MS conditions that interfere with walking performance.
Other
- Any current or recent exacerbations
- Any adverse reaction to antipyretics
Who the study is looking for
- A definitive MS diagnosis confirmed by self-report,
- The ability to walk for 2 minutes continuously with or without assistive device ---Age 18-65
- Provide a blood test within the last 6 months to 1 year reflecting normal liver and renal profile (normal liver enzymes and normal creatinine level).
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hunter College Physical Therapy department Coordinator of this site? Confirm its status | New York | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.